Industry Should Develop Narrower Indications First To Secure Market Access, AstraZeneca Exec Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Demonstrating superiority to standard of care or placebo in narrower indications will win over regulators, AstraZeneca Exec-VP John Patterson says at R&D conference in Geneva, Switzerland. Millennium followed a similar strategy to develop Velcade.